The inhibitors targeting HIF-1α also can inactivate the tumour microenvironment-derived extrinsic signals (CSF1 and CCL5) to further improve the response of targeting intrinsic molecular pathways to overcome the resistance to anti-VEGF therapy. This evidence concerns the gene CCL5 and neoplasm.